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Missing data are a common problem in epidemiologic
studies. This study had two aims: (a) to determine which
method for imputing missing renal function data provides
estimates closest to those made with complete data and
(b) to determine which measure of renal function better
estimates cardiovascular disease (CVD) risk. For these
analyses, a subset of Strong Heart Study participants with
complete data for renal function was identified. Data were
randomly dropped from this complete set at three rates: 30,
45, and 60%. Five common techniques for handling missing
data were compared: imputation using the mean, adjacent
value (AV), single imputation, multiple imputation, and
listwise deletion. Differences between the imputed sets and
the complete set were determined for each method.
Imputation methods were used to fill in missing values for
serum creatinine (Scr) in one model and estimated
glomerular filtration rate (eGFR) in another. For both Scr and
eGFR, the AV method provided the most favorable results in
predicting CVD risk, regardless of the rate of missing data.
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Missing data are common in epidemiologic studies and can
render findings nonsignificant or introduce bias.1,2 In
longitudinal studies, missing data result from mortality or
incomplete measures. Although dropping missing data can
limit generalization of the results, it is sometimes unavoid-
able. Alternatively, missing values may be imputed to
generate complete data.
Renal dysfunction is associated with cardiovascular disease
(CVD) mortality,3,4 and even mild-to-moderate kidney
impairment increases mortality and morbidity.5–8 Studying
kidney disease and CVD together is challenging because the
mortality associated with these diseases results in large
amounts of missing data.
Serum creatinine (Scr) is a direct screening test for kidney
function that is insensitive to early kidney disease.9
Glomerular filtration rate (GFR) is considered a superior
measure of kidney function.10 It is common in epidemiologic
studies to estimate GFR (eGFR).
Imputation using the mean, adjacent value (AV), single
imputation, multiple imputation (MI), and listwise deletion
(LD (i.e., dropping missing data)) are common techniques
for handling missing data. This study has two aims: (a) to
determine which imputation method yields renal function
measures closest to those observed in a complete set and
(b) to determine which renal function measure (Scr or eGFR)
provides results closest to those made from the complete set
in predicting CVD risk. We hypothesized that the MI method
would perform best.
RESULTS
Mean age in this cohort was 55.47 years (s.d.¼ 7.6 years);
61% of the participants were female (Table 1). Thirteen
percent had diabetes, and 17% experienced a CVD event
during follow-up. Mean Scr was 0.89 mg/ml (s.d.¼ 0.3 mg/
ml), and mean eGFR was 83 ml/min/1.73m2 (s.d.¼ 20 ml/
min/1.73m2).
Mean and 95% confidence intervals (CIs) of Scr and eGFR
resembled those of the complete data set at baseline
regardless of the rate of missing data in either renal measure
(Table 2).
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Compared with other imputation methods, the AV
method overestimated Scr across all levels of missing data
(Figure 1). In contrast to findings for Scr, AV provided the
closest estimates of true eGFR regardless of the rate of
missing data. The other methods performed variably
(Figure 2).
As expected, the complete case data using either renal
function measure showed significant relation to CVD risk.
The magnitude of risk associated with Scr was higher than
that for eGFR, however. Across imputation methods, Scr
yielded greater hazard ratios (HRs), regardless of the amount
of missing data (Table 3).
Differences in CVD prediction were evident from these
analyses. For both dichotomized Scr and eGFR, AV was the
only method that yielded significant results between renal
function and CVD risk consistent with the complete case
data; these results were robust even at 60% missing data.
Performance of the other methods varied and depended on
rate of missing data (Table 3). These methods generally
performed worse as the rate of missing data increased. At
higher levels of missing data, CVD risk was underestimated
regardless of renal function measure or imputation method.
To study decreased kidney function as a risk factor for CVD,
we performed a three-way comparison, in which we used
imputed Scr to calculate eGFR and then contrasted all three
renal function measures across the five imputation methods.
HRs associated with Scr were greater than those achieved
using the eGFR measures. Across imputation methods, few
differences were observed between the two eGFR measures
(Figure 3).
When continuous instead of dichotomous Scr and eGFR
were used, the ability of kidney function to predict CVD was
weaker. Results using continuous Scr varied by imputation
method and differed from those generated by the complete
case data (Table 4). Using continuous eGFR provided
estimates close to the complete case across the differently
imputed data sets.
DISCUSSION
Renal disease among American Indians is widespread, mainly
because of their high diabetes prevalence.11 Diminishing
renal function frequently occurs simultaneously with wor-
sening CVD risk factors, a phenomenon challenging to
longitudinal study of these diseases in populations where
both are common. The Strong Heart Study (SHS) provides
an opportunity to evaluate methods for imputing missing
renal function data with respect to achieving accurate
estimates of CVD risk. Our findings may provide guidance
for imputing missing data in other longitudinal studies
focusing on renal and CVD.
Several points warrant discussion with respect to predict-
ing CVD risk in the setting of missing renal data. As the
proportion of missing data increased, the imputation
methods worsened in estimating the association between
renal function and CVD. The exception to this observation
was the AV method, which yielded estimates close to the
complete data, regardless of the rate of missing data. This
Table 1 | Baseline characteristics of SHS participants with
complete renal data, N=2719, 1988–2002
N 2719
Age (mean7s.d.) years 55.4777.64
Females (%) 1705 (62)
Diabetes (%) 357 (13)
CVD (%) 465 (17)
Scr (mean7s.d.) mg/ml 0.8970.3
eGFR (mean7s.d.) ml/min/1.73m2 83720
CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; Scr, serum
creatinine.
Table 2 | Mean Scr and eGFR in the complete data set and at three rates of missing data
Complete data N=2719 30% missing N=812 45% missing N=1223 60% missing N=1637
Scr mean 95% CI 0.89 (0.88–0.91) 0.88 (0.87–0.89) 0.89 (0.87–0.91) 0.89 (0.87–0.91)
eGFR mean 95% CI 83.27 (82.52–84.02) 83.33 (81.87–84.78) 83.55 (82.39–84.69) 83.54 (82.51–84.57)
CI, confidence interval; eGFR, estimated glomerular filtration rate; Scr, serum creatinine.
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Figure 1 | Comparison of mean Scr in the imputed sets versus the
complete Strong Heart Study data set, at three levels of missing
data.
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Figure 2 | Comparison of mean eGFR in the imputed sets versus
the complete Strong Heart Study data set, at three levels of
missing data.
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finding was inconsistent with our hypothesis that the MI
method would perform best. Although the MI method is
often used when the proportion of missing data is large, it
performed poorly in this study, even at 30% missing data.
The AV method may perform better because it uses actual
data from adjacent measures and because renal dysfunction
often progresses slowly.
Estimating mean Scr and eGFR by imputing missing
values using the various techniques also yielded varied
results, some of which inconsistently predicted CVD risk. In
particular, the single imputation method performed worst
when used with eGFR, whereas the AV method performed
poorly with Scr. The divergence in estimates of mean Scr may
be because renal dysfunction progresses over time, making
use of the most AV problematic in estimating the mean,
especially when the value being imputed is based on an AV
that occurs subsequent to the missing value.
Another important consideration is the consistent
difference in CVD risk between both actual and
imputed measures of Scr and those for eGFR. eGFR
identifies renal dysfunction at an earlier stage than
Scr, which identifies a subset of individuals who are, on
average, less ill than those categorized by Scr.10 It was not
surprising that estimates of CVD risk associated with
abnormal Scr were consistently higher than those associated
with eGFR; CVD events were more common in the Scr
group.
LD is routinely used in analysis of longitudinal epide-
miologic data, but the strengths and limitations of this
method for a particular study are rarely discussed. The LD
method performed well in predicting CVD risk from Scr and
eGFR when the rate of missing data was 30% but not at
higher levels of missing data. Unlike the other methods, LD
discards incomplete observations, reducing power. The LD
method resulted in wider CIs, although these intervals did
not include 1.0.
These findings should be interpreted with caution. First,
our cohort was selected from those with complete kidney
data from the SHS; therefore, findings such as the prevalence
of diabetes do not match what has been reported in other
SHS publications. Furthermore, SHS renal function data were
collected at intervals of approximately 5 years. The AV
method, which performed well in this setting, may not
perform well in studies where AVs occur at longer intervals.
Thus, the performance of this method may depend on the
study design, visit schedule, and the natural progression of
the disease.
As in many epidemiologic studies, this study did not have
a direct assessment of GFR, such as renal clearance of 125I-
iothalamate. This report focuses on methods to approach
missing renal data, not the accuracy of these renal measures
against a gold standard, and the findings should be
interpreted in this context.
Table 3 | Adjusted hazard ratiosa with corresponding 95% CI for CVD risk by imputation method using dichotomized Scr and
eGFR
Complete data Mean AV SI MI Listwise deletion
Imputation method Factor HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
30% missing
Scr 2.05 (1.48–2.83)* 1.99 (1.37–2.88)* 2.01 (1.52–2.66)* 1.52 (1.15–1.99)* 1.57 (1.17–2.11)* 2.06 (1.41–3.01)*
eGFR 1.56 (1.16–2.11)* 1.47 (1.05–2.06)* 1.56 (1.20–2.03)* 1.27 (0.95–1.69) 1.37 (0.96–1.97) 1.55 (1.08–2.19)*
45% missing
Scr 2.05 (1.48–2.83)* 1.75 (1.14–2.68)* 2.15 (1.65–2.80)* 1.29 (0.98–1.68) 1.33 (0.89–1.96) 1.83 (1.17–2.84)*
eGFR 1.56 (1.16–2.11)* 1.28 (0.86–1.86) 1.66 (1.29–2.14)* 1.35 (1.03–1.79)* 1.25 (0.88–1.75) 1.34 (0.88–2.01)
60% missing
Scr 2.05 (1.48–2.83)* 1.29 (0.74–2.25) 2.04 (1.57–2.65)* 1.04 (0.92–1.59) 1.18 (0.73–1.92) 1.35 (0.76–2.41)
eGFR 1.56 (1.16–2.11)* 1.00 (0.62–1.62) 1.64 (1.28–2.09)* 1.13 (0.84–1.52) 0.99 (0.62–1.62) 1.04 (0.62–1.73)
AV, imputation using adjacent value; CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; MI, multiple imputation;
Scr, serum creatinine; SI, single imputation.
Mean=imputation using the mean.
aCox proportional regression models adjusted for age, gender, and diabetes.
*Significant at 5%.
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Figure 3 | HRs for the relationship among Scr, eGFR, eGFR
calculated using imputed Scr and risk of CVD from separate Cox
regression models, according to imputation method at 30%
missing data. The HR estimate is shown as a dot and the extended
horizontal line represents the 95% CIs. The complete case data set is
plotted as the first group in all three methods of measuring kidney
function.
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In summary, the AV method performs well in estimating
CVD risk associated with abnormal renal function, and this
method works well even when as many as 60% of the data are
missing. Deletion of missing observations, although resulting
in reduced power, yielded accurate risk estimates when the
rate of missing data was relatively low. AV and LD, therefore,
appear to be good choices for handling missing renal
function data.
MATERIALS AND METHODS
The SHS cohort of 4549 American Indians includes men and
women aged 45–74 seen at three examinations (1989–1991,
1993–1995, and 1998–2000).12,13
Criteria used to define definite fatal myocardial infarction,
stroke, coronary heart disease, and nonfatal CVD have been
published14 as have methods for ascertaining CVD events.12,15,16
Diabetes was defined by American Diabetes Association criteria.17
Plasma creatinine measures were performed by a single core
laboratory and determined by enzymatic methods.12,15 Urinary
creatinine was measured at all three exams.18,19 The abbreviated
Modification of Diet in Renal Disease equation was used to calculate
eGFR:
eGFR¼ 86 (SCR)1.154AGE0.203 (0.742 if female) (1.210
if African-American)20
As SHS includes only American Indians, the Modification of Diet
in Renal Disease term for ethnicity was the same for all participants.
We identified a subset of 2719 SHS participants with complete
renal data for all three examinations and complete follow-up data
for CVD events. We considered two different types of analysis: in
one model, we used Scr and eGFR as continuous variables, and, in
another, as categorical variables. Abnormal GFR was defined as
eGFRo60 ml/min/1.73m2.10 This eGFR cutoff was used to estimate
thresholds of abnormal Scr based on median age of men and women
independently (1.4 and 1.1 mg/dl, respectively).
Data were randomly dropped using an algorithm created in SAS
by assigning a value between 0 and 1 to each observation. Varying
ranges of cutoff values were assigned to observations, and the
corresponding renal data were dropped. We examined the
performance of the imputation methods at three levels of missing
data: 30, 45, and 60%.
We assessed five methods for imputing missing data: (a) the
overall mean, in which overall Scr mean and overall eGFR mean
from Exam 1 were used to impute missing Scr and eGFR scores; (b)
AV, in which we focused our analyses on baseline data and used data
from Exam 2 to impute data missing from Exam 1; (c and d) single
imputation and MI where we imputed missing data using PROC MI
in SAS and MCMC to accommodate arbitrary missing patterns,
used PROC MIANALYZE in SAS to combine the estimated
parameters in the 10 imputed data sets with the MI method, and
considered age, gender, and diabetes; and (e) LD, in which we
dropped observations with missing data. Each method was used to
fill in missing values for Scr in one model and eGFR in another.
Statistical analysis
Means with corresponding 95% CIs of Scr and eGFR were generated
by each set of imputed data and compared with means from the
complete data. Using PROC PHREG in SAS, Cox proportional
hazard regression models were used to analyze the association
between kidney function measured by Scr and eGFR at Exam 1 and
subsequent risk of CVD. Scr was used in one model and eGFR in
another. HRs and 95% CIs were calculated and adjusted for age,
gender, and diabetes. Dichotomous Scr and eGFR variables using
defined thresholds for both renal function measures were used in
some models, whereas continuous Scr and eGFR were used in
others. The imputations were performed on continuous Scr and
eGFR.
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Table 4 | Adjusted hazard ratiosa with corresponding 95% CI for CVD risk by imputation method using continuous Scr and
eGFR
Complete Data Mean AV SI MI Listwise deletion
Imputation method Factor HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
30% missing
Scr 1.29 (1.11–1.51)* 1.27 (1.11–1.50)* 1.29 (1.17–1.40)* 1.34 (1.17–1.53)* 1.29 (1.11–1.50)* 1.28 (1.09–1.51)*
eGFR 0.99 (0.99–1.0) 0.99 (0.98–0.99) 0.98 (0.98–0.99) 0.99 (0.98–1.0)* 0.99 (0.98–0.99) 0.99 (0.98–1.0)
45% missing
Scr 1.29 (1.11–1.51)* 1.24 (0.99–1.55) 1.23 (1.14–1.33)* 1.19 (0.96–1.48) 1.26 (1.02–1.56) 1.25 (1.0–1.55)
eGFR 0.99 (0.99–1.0) 0.99 (0.98–1.0) 0.99 (0.98–1.0) 0.99 (0.98–1.0) 1.0 (1.0–1.01) 0.99 (0.98–0.99)
60% missing
Scr 1.29 (1.11–1.51)* 1.16 (0.84–1.61) 1.25 (1.16–1.34)* 1.1 (0.82–1.45) 1.14 (0.71–1.82) 1.15 (0.81–1.63)
eGFR 0.99 (0.99–1.0) 0.99 (0.98–1.01) 0.99 (0.98–0.99) 0.99 (0.99–1.00) 0.99 (0.98–1.0) 0.99 (0.98–1.01)
AV, imputation using adjacent value; CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; MI, multiple imputation;
Scr, serum creatinine; SI, single imputation.
Mean=imputation using the mean.
aCox proportional regression models adjusted for age, gender, and diabetes.
*Significant at 5%.
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